Mike Bonney joins the Kaleido team from Cubist Pharmaceuticals, where he served as CEO and Director and led it to become the world’s leading antibiotic company, which was acquired by Merck for $9.5 billion in 2015. At Cubist, Bonney oversaw the development and release of the antibiotic Cubicin – the most successful launch of an antibiotic in American history. Prior to Cubist, Bonney worked at Biogen, where he launched one of the leading MS drugs in the United States, Avonex, which experienced tremendous commercial success. Mike chairs the Board of Alnylam Pharmaceuticals and the Bates College Board of Trustees. He also serves as a board member of CELGENE, the Whitehead institute for Biomedical Research and others. Recently, Bonney was a national finalist in Ernst & Young’s Entrepreneur of the year, and was recognized as the Top CEO in Massachusetts by the Boston Globe. In 2011, he was also one of six executives nationwide to be named “Best CEO in the Country” by MarketWatch.
Alison Lawton brings to Kaleido more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. Prior to joining Kaleido, Ms. Lawton was chief operating officer at Aura Biosciences, and previously held the same role at OvaScience. She spent more than 20 years in various positions of increasing responsibility at Genzyme Corporation and subsequently as part of Sanofi, following its 2011 acquisition of Genzyme. At Genzyme, Ms. Lawton served as Senior Vice President and General Manager of the company’s biosurgery unit, where she was responsible for global orthopedics, surgical and regenerative medicine businesses, and also oversaw global market access, including regulatory affairs, health outcomes and global policy. Previously, Ms. Lawton worked for seven years in the United Kingdom at Parke-Davis. She is a member of the board of directors of ProQR Therapeutics, Verastem Inc., and Magenta Therapeutics. She earned her Bachelor of Science degree in Pharmacology from King’s College London.
Geoffrey von Maltzahn is a leading innovator and entrepreneur in the microbiome and biotechnology and is a co-founder of companies that have achieved over $3 billion in private and public market capitalization. He is a partner at Flagship Pioneering and has co-founded multiple biotech companies including Seres Therapeutics (NASDAQ: MCRB), Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals (NASDAQ: SNNA). He recently served as the President of Indigo, where he led the creation of the world’s largest plant microbiome database and development of the company’s first commercial products. Von Maltzahn is an inventor on more than 100 patents and patent applications in biotech, nutrition and microbiome-based technologies and has been recognized with numerous awards, including the prestigious Lemelson-MIT student prize, given to the most innovative student at MIT. Von Maltzahn’s innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. He received his PhD from MIT in the Harvard-MIT Division of Health Sciences and Technology.
Ruth Thieroff-Ekerdt brings more than 30 years of broad global experience in pharmaceutical R&D, with leadership roles in discovery, early and late stage development, launch and medical accountability for commercial products in EU and US in diverse therapeutic areas including GI, endocrine, autoimmune, and rare disorders, as well as products in women’s health, OTC and nutrition products. With her successful track record to managing the scientific, operational and regulatory dimensions of the drug development process from research labs to global approval and beyond, she has grown and launched more than 20 products in various regulatory and market environments. Before Kaleido, she served as CMO of both Aptalis (acquired by Forest Labs for $2.9 billion) and Eurand (acquired by Axcan for more than $500 million). Most recently, she served as CMO of Strongbridge Biopharma, where she oversaw its Phase 3 program for levoketoconazole in endogenous Cushing’s syndrome and worked with the CEO to raise over 100 Mio and taking the company public in the US (NASDAQ: SBBP).
Joshua Brumm has more than a decade of operations, finance and investment banking experience in the life science industry. Most recently, Mr. Brumm served as CFO and chief operating officer at Versartis, Inc., where he oversaw the company’s financial strategy, helped negotiate the company’s first product partnership and led the successful completion of a $145 million initial public offering. Prior to that, he was executive vice president of finance and principal financial officer at Pharmacyclics, Inc., CFO at ZELTIQ Aesthetics, Inc. and director of finance at Proteolix, Inc. Over the course of his career in corporate finance, Mr. Brumm has raised more than $700 million in equity financings, completed two initial public offerings and was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million in 2014. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. He holds a B.A. in Business Administration from the University of Notre Dame.
Jeremy Buzzard guides Kaleido’s corporate and portfolio strategy, transactions and commercial execution with a passion for maximizing the improvements Kaleido can bring to people’s lives. Prior to joining Kaleido, Jeremy spent more than 10 years advising executive teams and boards of multinational healthcare companies as a partner at McKinsey & Company in New York, where he co-led the firm’s global healthcare strategy and corporate finance practice. During his time at McKinsey, Jeremy served clients spanning Biotech, MedTech, Specialty Pharmaceuticals and Medical Devices. His experience included leading teams that created two multi-billion dollar public companies, supporting the planning and execution of four of the largest drug launches in the last decade, designing and executing the integration of 15 transformational acquisitions, and leading strategic diligence for more than 55 transactions including 25 that were executed (with an aggregate value of $56Bn). Before joining McKinsey, Jeremy was a research scientist at ESI Bio, a startup company in Singapore. He holds a PhD in Cell and Molecular Biology from Monash University, with postdoctoral experience at Harvard University.
Dr. Miller oversees the consumer product research and development pipeline at Kaleido, following a successful 30 year career at Abbott Nutrition. Miller was responsible for global pediatric, adult, and performance nutrition product development, innovation, new ventures, medical safety, clinical and preclinical research as the Divisional Vice President of R&D, Scientific and Medical Affairs at Abbott Nutrition, and was part of the Executive team managing the $7 billion nutrition business. He was an architect of the global expansion of Abbott Nutrition, establishing R&D Centers in Singapore, Shanghai, China and Bangalore, India. Dr. Miller was co-chair of the Abbott Scientific Governing Board from 2013-2016, overseeing talent development and program efforts of Abbott’s 2,500 scientists for all Abbott Laboratories divisions. He continues to develop leadership potential in scientists through his responsibilities as a Commissioner for the Food Systems Leadership Institute part of the Association of Public and Land Grant Universities. Miller holds a Ph.D. in Nutritional Biochemistry from the University of Wisconsin-Madison, and completed a Staff fellowship at the National Institute of Health.
John W. Davies, Ph.D. will oversee the research and technology platform for Kaleido. John has more than 25 years of experience creating and leading diverse technology teams. He received his Ph.D. in synthetic organic chemistry from University College London, before embarking on postdoctoral studies in the emerging field of computational modeling at GlaxoSmithKline. In 1992, Dr. Davies joined Sandoz in London to carry out computational research in neuroscience, before moving to the United States where he supported a broad range of therapeutic disease areas. John held increasing responsibility for technology disciplines and, at Novartis, was responsible for early discovery informatics, sample management, robotics and automation. During this time, he spearheaded the installation of the new automation platform for high-throughput screening (HTS) and initiated the development of a new $25 million sample management environment in Cambridge. Computationally, he led an initiative that reshaped the data and computational strategy for the Novartis Institutes for BioMedical Research (NIBR) and developed a number of unique industry-leading computational approaches, which resulted in more than 100 publications across the informatics group.
Michael Bruce brings more than 20 years of pharmaceutical and biotech product development experience to Kaleido. Michael was one of the earliest hires at CRISPR Therapeutics, where he built the project, portfolio and alliance management functions, including the buildup and successful launch of alliances with Vertex and Bayer. Michael also worked on product development at Millennium Pharmaceuticals, and joined Wyeth, where he led oncology drug development projects. He was a contributing leader to the successful development of five globally marketed drug products. Michael also led project and portfolio management functions at Pfizer, ultimately leading the project management group and governance bodies for the Phase 0-2 portfolio. He has a B.A. from Williams College and a Ph.D. from Stanford University.
Ms. Arnold brings more than 20 years of experience in human resources to Kaleido, including extensive work in the biopharmaceutical industry. Prior to joining Kaleido, Ms. Arnold was head of the HR business partnership function at Moderna Therapeutics, and helped lead the HR organization during a period of significant growth, including implementing talent and engagement initiatives, compensation framework and benefits program enhancements. Prior to that, she was at Celgene Avilomics Research (formerly Avila Therapeutics) where she was responsible for building and developing the HR infrastructure for the company’s early research and development division. She also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold received her Bachelor of Science degree from Colorado State University.
Ms. Stewart has worked for more than 25 years in biopharmaceutical regulatory affairs, with significant experience devising innovative strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. Previously, in addition to being an independent regulatory consultant for several years, she was senior vice president of regulatory affairs, quality, and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular. She also spent more than 10 years at Genzyme Corporation in regulatory and compliance roles, including serving as vice president, regulatory affairs. She received her J.D. from Concord Law School at Purdue University Global and her B.A. from the University of Massachusetts.
Dr. Sofen brings to Kaleido extensive experience in technical innovation, product development and manufacturing, including more than 15 years in the biotechnology industry. Most recently, he was a vice president of technical operations at CRISPR Therapeutics, where he built and led the company’s process development, analytical sciences and manufacturing capabilities. Dr. Sofen also held senior technology and operations positions at Biogen, Genzyme Corporation and the Novartis-MIT Center for Continuous Manufacturing. He received his Ph.D. in bioinorganic chemistry from University of California, Berkley and his B.A. from Reed College.
Jeff Moore brings more than 20 years of financial and operations experience in life science technology and Big 4 accounting to Kaleido. Prior to joining Kaleido, he was SVP, Finance and Operations for Axcella Health. In addition, Moore has gained a wealth of experience building rapidly emerging life science companies serving as Chief Financial Officer or in other senior financial and operational roles for number of companies including Helicos BioSciences (NASDAQ: HLCS), Joule Unlimited, BG Medicine (NASDAQ: BGMD), Affinnova, Inc., and Flagship Ventures. Prior to joining Flagship Ventures, Moore served as the Director of Business Analysis and Planning at Celera Genomics, the first biotechnology firm to sequence the human genome, and as Vice President, Treasury Operations and Chief Accounting Officer at PerSeptive Biosystems (NASDAQ: PBIO). Moore started his career with Price Waterhouse in its Emerging Growth Company practice providing audit and advisory services to both private and public life science and technology companies. Moore received his Bachelors of Science degree from Cornell University and a Masters of Business Administration degree from Vanderbilt University.
Flagship Pioneering is a fully-integrated life science innovation enterprise that conceives, creates, resources and develops first-in-category companies. In Flagship VentureLabs®—Flagship’s innovation foundry—the firm’s scientific entrepreneurs evolve ideas into new fields or advance previously undiscovered areas of science into real-world inventions and ventures. Since its launch in 2000, Flagship has applied this unique, hypothesis-driven innovation process to originate and foster nearly 100 scientific ventures, resulting in over $20 billion in aggregate value, 500+ issued patents and more than 45 clinical trials for novel therapeutic agents.
If you are passionate about creating the future of microbiome healthcare, we'd love to speak with you.Let's start a conversation